Open Access Green as soon as Postprint is submitted to ZB.
Immuno-PET imaging of engineered human T cells in tumors.
Cancer Res. 76, 4113-4123 (2016)
Publ. Version/Full Text
Supplement
DOI
PMC
Sensitive in vivo imaging technologies applicable to the clinical setting are still lacking for adoptive T-cell-based immunotherapies, an important gap to fill if mechanisms of tumor rejection or escape are to be understood. Here, we propose a highly sensitive imaging technology to track human TCR-transgenic T cells in vivo by directly targeting the murinized constant TCR beta domain (TCRmu) with a zirconium-89 ((89)Zr)-labeled anti-TCRmu-F(ab')2 fragment. Binding of the labeled or unlabeled F(ab')2 fragment did not impair functionality of transgenic T cells in vitro and in vivo Using a murine xenograft model of human myeloid sarcoma, we monitored by Immuno-PET imaging human central memory T cells (TCM), which were transgenic for a myeloid peroxidase (MPO)-specific TCR. Diverse T-cell distribution patterns were detected by PET/CT imaging, depending on the tumor size and rejection phase. Results were confirmed by IHC and semiquantitative evaluation of T-cell infiltration within the tumor corresponding to the PET/CT images. Overall, these findings offer a preclinical proof of concept for an imaging approach that is readily tractable for clinical translation.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Positron-emission-tomography; Metastatic Prostate-cancer; In-vivo Tracking; Monoclonal-antibody; Antileukemic Reactivity; Noninvasive Detection; Gene-therapy; Receptor; Lymphocytes; Antigen
ISSN (print) / ISBN
0008-5472
e-ISSN
1538-7445
Journal
Cancer Research
Quellenangaben
Volume: 76,
Issue: 14,
Pages: 4113-4123
Publisher
American Association for Cancer Research (AACR)
Publishing Place
Philadelphia, Pa.
Non-patent literature
Publications
Reviewing status
Peer reviewed